| AIFA | Italian Medicines Agency |
| ALT | Alanine aminotransferase |
| ARTHE | Avidination for Radionuclide Therapy in Nonpalpable Breast Cancer |
| BI-RADS | Breast Imaging Reporting and Data System |
| CI | Confidence interval |
| CTCAE | Common Terminology Criteria for Adverse Events |
| DLT | Dose-limiting toxicity |
| DOTA | 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid |
| ECOG | Eastern Cooperative Oncology Group |
| GCP | Good Clinical Practice |
| GMP | Good Manufacturing Practice |
| HER2 | Human epidermal growth factor receptor 2 |
| HPLC | High-performance liquid chromatography |
| IART | Intraoperative avidination for radionuclide therapy |
| IQR | Interquartile range |
| IRST | Istituto Romagnolo per lo Studio dei Tumori |
| PET/CT | Positron emission tomography/computed tomography |
| pCR | Pathologic complete response |
| r-BHD | Reduced biotinamidohexylamine-DOTA |
| RTC | Residual tumor cellularity |
| RTOG | Radiation Therapy Oncology Group |
| SPECT/CT | Single-photon emission computed tomography/computed tomography |
| TLC | Thin-layer chromatography |
| VABB | Vacuum-assisted breast biopsy |
| WHO | World Health Organization |